Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
DE0006632003
Tue, 09.11.2021
MorphoSys AG
Media Release
MorphoSys Announces Departure of Roland Wandeler
Planegg/Munich, Germany, November 9, 2021 - MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that Roland Wandeler, Ph.D., has decided to step down from his position as Chief Operating Officer (COO) and member of the MorphoSys Management Board effective December 31, 2021 to pursu [ … ]
Thu, 04.11.2021
MorphoSys AG
MorphoSys presents interim results from M-PLACE study with felzartamab during American Society of Nephrology Annual MeetingFelzartamab has the potential to rapidly and substantially reduce anti-PLA2R antibody titers in patients with anti-PLA2R-positive membranous nephropathy
MorphoSys AG (FSE: MOR; NASDAQ: MOR) presented interim results from the M- [ … ]
Thu, 04.11.2021
MorphoSys AG
MEDIA RELEASE
MorphoSys to present MANIFEST and RE-MIND2 data from expanded hematology-oncology portfolio at the 2021 American Society of Hematology (ASH) Annual Meeting- Updates from MANIFEST phase 2 trial in patients with myelofibrosis, including clinical updates on JAK naïve patients treated with pelabresib in combination with ruxolitinib, incl [ … ]
Tue, 02.11.2021
MorphoSys AG
Media Release
Planegg/Munich, Germany, November 02, 2021
MorphoSys AG announces Monjuvi(R) Sales for the First Nine Months and Third Quarter of 2021 and Invitation to the upcoming Conference Call on November 11, 2021
MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announces that revenues from product sales of Monjuvi(R) (tafasitamab-cxix) in the U.S. [ … ]
Wed, 20.10.2021
MorphoSys AG
First Patient Dosed in Phase 2 IGNAZ Study of Felzartamab in Patients with Immunoglobulin A Nephropathy
MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that the first patient has been dosed in the Phase 2 IGNAZ clinical trial evaluating felzartamab for patients with Immunoglobulin A Nephropathy (IgAN). IgAN, also known as Berger's disease, is [ … ]
Mon, 11.10.2021
MorphoSys AG
Media Release
Planegg/Munich, Germany, October 11, 2021
MorphoSys' Licensing Partner Roche Received Breakthrough Therapy Designation for Gantenerumab in Alzheimer's Disease
MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that its licensing partner Roche (SIX: RO, ROG; OTCQX: RHHBY) received Breakthrough Therapy Designation by the U.S. Food [ … ]
Thu, 26.08.2021
MorphoSys AG
MorphoSys and Incyte Announce the European Commission Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
-The decision by the European Commission is based on data from the L-MIND study evaluating tafasitamab in combination with lenalidomide [ … ]
Tue, 24.08.2021
MorphoSys AG
Health Canada Grants Marketing Authorization for Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Minjuvi is a new therapeutic option for eligible patients with DLBCL in Canada to address an urgent unmet medical need
PLANEGG/Munich, Germany, - August [ … ]
Tue, 17.08.2021
MorphoSys AG
Media ReleaseMorphoSys' Partner Incyte Announced Development and Commercialization Agreement with InnoCare for Tafasitamab in Greater China
Planegg/Munich, Germany - August 17, 2021 - MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that Incyte, its development and commercialization partner for tafasitamab, entered into a collaboration and lic [ … ]
Wed, 28.07.2021
MorphoSys AG
Media Release
MorphoSys AG Reports Second Quarter and First Half 2021 Results
- Monjuvi U.S. net product sales of € 14.9 million (US$ 18.0 million), 16% growth Q-Q
- MorphoSys announced and subsequently completed its acquisition of Constellation Pharmaceuticals
- Announced and closed ~US$ 2.0 billion strategic funding partnership with Royalty Ph [ … ]